Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Sotio Biotech Inc.
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
VM Oncology, LLC
Incyte Corporation
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Incyte Corporation
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
SOLTI Breast Cancer Research Group
Alliance for Clinical Trials in Oncology
University of Leeds
Kyowa Kirin Co., Ltd.
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital
Translational Research in Oncology
Jules Bordet Institute
Xencor, Inc.
Incyte Corporation
Rijnstate Hospital
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Incyte Corporation
Jonsson Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Stanford University
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Novartis
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mannkind Corporation